SCHEMBL4484450

SCHEMBL4484450

OB(O)c1cc(Cl)ccn1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR4A2 P43354 3/20 0.38
ALDH1A1 P00352 1/20 0.37
MAPT P10636 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
ENPP2 Q13822 2/20 0.36
SOS2 Q07890 1/20 0.34
KDM4C Q9H3R0 1/20 0.34
MAP3K14 Q99558 2/20 0.33
ROCK1 Q13464 2/20 0.33
RECQL P46063 1/20 0.33
CDC7 O00311 1/20 0.33
CDK2 P24941 1/20 0.33
EGFR P00533 1/20 0.32
LMNA P02545 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
HTR3E A5X5Y0 1/20 0.32
HTR3B O95264 1/20 0.32
HTR3A P46098 1/20 0.32
HTR3D Q70Z44 1/20 0.32
HTR3C Q8WXA8 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28507681 0.74 KDM4E (0.47) ALDH1A1MAP3K14ROCK1CDC7CDK2
SCHEMBL1404632 0.74 ENPP2 (0.38) ALDH1A1ENPP2
SCHEMBL28668509 0.74 ENPP2 (0.38) ALDH1A1ENPP2CDC7CDK2LMNA
SCHEMBL1843835 0.73 UHRF1 (0.50) ALDH1A1L3MBTL1ROCK1LMNASMN1; SMN2
SCHEMBL17181769 0.73 ASIC3 (0.41) NR4A2ALDH1A1MAPTENPP2KDM4C
SCHEMBL29952078 0.73 UHRF1 (0.50) ALDH1A1L3MBTL1ROCK1LMNASMN1; SMN2
SCHEMBL29954387 0.73 KMO (0.34) ALDH1A1KDM4CROCK1CDC7CDK2
SCHEMBL1843516 0.73 KMO (0.34) ALDH1A1KDM4CROCK1CDC7CDK2
SCHEMBL29798588 0.69
SCHEMBL135549 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 US disclosed
US-7615639-B2 1-pyridyl-benzofuro[3,2-b]pyridin-2(1H)-ones TIBOTEC PHARMACEUTICALS, LTD. (IE) 2009-11-10 US disclosed
US-20070265295-A1 1-Heterocyclyl-1,5-Dihydro-Pyrido[3,2-B]Indol-2-Ones TIBOTEC PHARMACEUTICALS LTD. (IE) 2007-11-15 US disclosed
EP-1758911-A1 1-HETEROCYCLYL-1,5-DIHYDRO-PYRIDO[3,2-B]INDOL-2-ONES Tibotec Pharmaceuticals Ltd. (IE) 2007-03-07 EP disclosed
WO-2005111047-A1 1-HETEROCYCLYL-1,5-DIHYDRO-PYRIDO[3,2-B]INDOL-2-ONES TIBOTEC PHARMACEUTICALS LTD. (IE) 2005-11-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070265295-A1 1-Heterocyclyl-1,5-Dihydro-Pyrido[3,2-B]Indol-2-Ones CBR1, HRH4, CYP4B1 NR4A2 17/4885ALDH1A1 984/4885MAPT 4870/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.